NCT01230697|UnknownDMC
Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM)
SORHORM
Loading search results
SORHORM
Sponsor study identifier
observational
60
1 country
1
Study Start
June 2010
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
August 2010
Actual (reported)Study Completion
September 2011
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The study includes the recruitment of patients with advanced renal cells carcinoma and hepatocarcinoma in treatment with sorafenib. Multicenter cohort study. It is a prospective observational study.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2011
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 2010
Date type not reportedThis date has not been verified as actual or estimated.
August 2010
Actual (reported)September 2, 2010
Actual (reported)October 29, 2010
Actual (reported)September 2011
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Identify the value variations of hormones involved in phosphate homeostasis during sorafenib administration
Assess the effects of sorafenib hormones involved in phosphate homeostasis
one year
Identify metabolic differences between renal cells cancer and hepatocarcinoma
one year
Identify variations on bone mass during sorafenib treatment
one year
Identify correlations between phosphate related hormones and side effects during sorafenib treatment as a Measure of safety and tolerability
one year
Identify correlations between phosphate related hormones variations and patients outcome (TTP and overall survival)
one year
Patients with advanced renal cells carcinoma and hepatocarcinoma in treatment with Sorafenib
Sorafenib 800mg/die oral
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients with advanced renal cells carcinoma and hepatocarcinoma
Alfredo Berruti
Orbassano (To), Turin, 10043, Italy
Serum analites involved in phosphate homeostasis
First Submitted
September 2, 2010
First Posted
October 29, 2010
Study Start
June 2010
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
August 2010
Actual (reported)Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Contact the study team to confirm eligibility.
Study Completion
September 2011
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
October 29, 2010
Record last verified: 2010-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: